San Francisco, CA, United States of America

John Kollins

This inventor holds 3 USPTO granted patents and 5 published patent applications and 1 EPO patent. Top assignee: Satsuma Pharmaceuticals, Inc.. Active years: 2020-2026.

USPTO Granted Patents = 3 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2020-2026

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: John Kollins: Innovator in Headache Treatment

Introduction

John Kollins is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment and prevention of headaches. With a total of 3 patents to his name, Kollins is recognized for his innovative approaches to healthcare.

Latest Patents

Kollins' latest patents focus on compositions, devices, and methods for treating or preventing headaches. These patents disclose pharmaceutical compositions and devices, along with their combinations and uses, aimed at alleviating headache symptoms. His work in this area demonstrates a commitment to improving patient care and enhancing the quality of life for those suffering from headaches.

Career Highlights

Currently, John Kollins is employed at Satsuma Pharmaceuticals, Inc., where he continues to develop groundbreaking solutions in the pharmaceutical industry. His expertise and dedication have positioned him as a key player in the field of headache treatment.

Collaborations

Throughout his career, Kollins has collaborated with esteemed colleagues, including Fumiyoshi Iwashima and Detlef Albrecht. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

John Kollins is a prominent inventor whose work in headache treatment has the potential to make a significant impact in the pharmaceutical industry. His patents and collaborations reflect a dedication to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…